Viking Therapeutics Inc. recently released a corporate presentation highlighting its ongoing efforts in developing novel therapeutics for metabolic and endocrine diseases. The presentation outlines multiple clinical programs, including VK2735, a GLP-1/GIP dual agonist for obesity, which successfully achieved its primary endpoint in the Phase 2 VENTURE study, with a Phase 3 trial planned for the second quarter of 2025. The oral version of VK2735 is currently in Phase 2, following positive proof-of-concept results in Phase 1. Additionally, an amylin agonist for obesity is in the pipeline, with an investigational new drug application planned for the fourth quarter of 2025. Other programs include VK2809, a selective thyroid receptor-β agonist for MASH, and VK0214, a selective thyroid receptor-β agonist for X-ALD, both of which have shown promising results in recent trials. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。